Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study - Wikidata - wikimedia - TriplyDB

Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study

Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study

http://www.wikidata.org/entity/Q28273981

about

Extensively drug-resistant tuberculosis: epidemiology and management Multidrug and extensively drug-resistant tuberculosis in Canada 1997-2008: demographic and disease characteristics Incidence and risk factors for extensively drug-resistant tuberculosis in Delhi region Enhancing hit identification in Mycobacterium tuberculosis drug discovery using validated dual-event Bayesian models Mortality among MDR-TB cases: comparison with drug-susceptible tuberculosis and associated factors Drug Susceptibility Patterns in MDR-TB Patients: Challenges for Future Regimen Design. A Cross-Sectional Study Discordance across Phenotypic and Molecular Methods for Drug Susceptibility Testing of Drug-Resistant Mycobacterium tuberculosis Isolates in a Low TB Incidence Country A Web-Based Platform for Designing Vaccines against Existing and Emerging Strains of Mycobacterium tuberculosis Major Challenges in Clinical Management of TB/HIV Coinfected Patients in Eastern Europe Compared with Western Europe and Latin America Association between Regimen Composition and Treatment Response in Patients with Multidrug-Resistant Tuberculosis: A Prospective Cohort Study Tradeoffs in Introduction Policies for the Anti-Tuberculosis Drug Bedaquiline: A Model-Based Analysis Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies.Predictors of pulmonary tuberculosis treatment outcomes in South Korea: a prospective cohort study, 2005-2012 Treatment practices, outcomes, and costs of multidrug-resistant and extensively drug-resistant tuberculosis, United States, 2005-2007.Risk factors associated with multidrug-resistant tuberculosis in Espírito Santo, Brazil.The structural modeling of the interaction between levofloxacin and the Mycobacterium tuberculosis gyrase catalytic site sheds light on the mechanisms of fluoroquinolones resistant tuberculosis in Colombian clinical isolates.Low Levels of Extensively Drug-resistant Tuberculosis among Multidrug Resistant Tuberculosis Isolates and Their Relationship to Risk Factors: Surveillance in Tehran, Iran; 2006 to 2014.Drug-resistant tuberculosis in Zhejiang Province, China: an updated analysis of time trends, 1999-2013 Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis.Unemployment in TB patients - ten-year observation at regional center of pulmonology in Bydgoszcz, Poland The HIV epidemic in Eastern Europe and Central Asia.DNA consensus sequence motif for binding response regulator PhoP, a virulence regulator of Mycobacterium tuberculosis.Multidrug-resistant tuberculosis in Europe, 2010-2011 Systematic review and meta-analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis.Target product profile of a molecular drug-susceptibility test for use in microscopy centers.Additional drug resistance of multidrug-resistant tuberculosis in patients in 9 countries.NMR Metabolomics Analysis of Parkinson's Disease A Novel Reporter Phage To Detect Tuberculosis and Rifampin Resistance in a High-HIV-Burden Population.Phenotypic and genotypic diversity in a multinational sample of drug-resistant Mycobacterium tuberculosis isolates.Determinants of multidrug-resistant tuberculosis in Henan province in China: a case control study.Later emergence of acquired drug resistance and its effect on treatment outcome in patients treated with Standard Short-Course Chemotherapy for tuberculosis.Treatment outcomes among drug-susceptible tuberculosis patients in Latvia, 2006-2010.Impact of the Mycobaterium africanum West Africa 2 Lineage on TB Diagnostics in West Africa: Decreased Sensitivity of Rapid Identification Tests in The Gambia Persistently high prevalence of primary resistance and multidrug resistance of tuberculosis in Heilongjiang Province, China.A High-Throughput Assay for Developing Inhibitors of PhoP, a Virulence Factor of Mycobacterium tuberculosis Multidrug-Resistant Tuberculosis Treatment Outcomes in Relation to Treatment and Initial Versus Acquired Second-Line Drug Resistance Challenges and controversies in defining totally drug-resistant tuberculosis.Improved survival in multidrug-resistant tuberculosis patients receiving integrated tuberculosis and antiretroviral treatment in the SAPiT Trial The heterogeneous evolution of multidrug-resistant Mycobacterium tuberculosis.

P2860

Q26830094-FAC97363-D26B-4664-809E-3D62D37999F5 Q28484917-92E92C47-6EC1-438B-8EE9-1C85354F7E27 Q28485946-92839510-CEB0-4770-BBB8-47FEFFE82E30 Q28487748-0626C059-62BF-4DCF-903F-99D7323E611F Q28544684-9137CD32-9547-4F47-B6E8-6CD8ECDA9EEE Q28550883-1A66E4B9-CE0B-41B1-84FF-69E5EF42C670 Q28551469-07DC724F-6D9F-47F8-BB22-68BD28A8265D Q28551471-9B3BCA48-3642-430A-8C23-FBDF6A02578E Q28551909-0F7539CD-2791-4C0D-BD4C-15E0BCD10804 Q28552001-AD50B03B-8F9A-487B-B6EB-A91CCFC3F3FA Q28554607-E40E61C8-94DD-4FB7-AD3B-2C64FDC4E0C0 Q30901894-09CD151D-3BFA-445A-B669-002121358F87 Q31170909-41038FDC-4F6B-481E-A97C-9F858FE2CA94 Q33577145-0729EDE5-058A-41A3-810A-188F8B80FB68 Q33578879-ABB85359-F10B-4908-8D45-4CBE4C120433 Q33616718-D6A35822-6909-47B5-AC88-5330560D7B3F Q33718580-8EE18F3C-27F4-41A7-B55E-14ED95D7F690 Q33867704-228283CD-E85B-48AB-8232-A6AAE3785353 Q33926262-B28CA0A4-9210-4966-BC9F-BAE4AA4C04D5 Q34285599-85278258-94EC-4976-A533-94B9DA30F09C Q34496018-A95442D7-01B6-487F-898C-7D5B91789E29 Q34660521-9C8B5CE6-E3FF-4343-82D9-22AF39DEC1F3 Q34822262-E9A67C14-1082-4503-8DC3-314C655F4526 Q35130346-88CB3DD7-D1C9-44E0-BBF7-6CE1CE000DDC Q35568367-FFE26C94-1A5A-4FB7-8048-FF55D64F5DF3 Q35588123-27BC7CAE-E906-42F2-AC2F-B8BB0A79DD19 Q35673425-DB80368A-157F-48D7-B948-8B5AFF20092E Q35734379-D4DD673D-DC4C-417F-B6D7-97FA812DB658 Q35757708-25C3BBB6-4D97-4F98-BB66-BDD616DF7811 Q35828310-171A1F48-3E86-4B6B-91E7-F0A54D4F87C1 Q35896082-9F2F4C7D-7A9D-44C4-8AEF-5AFCEBBC1A0B Q35914813-B7E16808-52D9-43A1-AC8E-881C67C0A246 Q35990660-3D72CCDA-66F1-46C3-8FD4-7375B327202B Q36069851-A05F7ACF-F075-4F1B-B3A3-C0C4D8C20D4B Q36145384-589CBAFB-D985-44CC-9494-86CB25E5688B Q36164838-7B1802BF-A7C8-4C7A-93EC-DF4192F34EE8 Q36497854-AC343BF8-22B6-4F86-875F-ADB4D04CF7F8 Q36574273-AB01A38C-3AE2-4127-B544-2FA39ED6D0B8 Q36627292-BE7FBACB-BBE4-4393-BFD2-06EB0F1887F4 Q36675409-88E6619B-11AB-4B25-B9E2-F09C86FF5BEC

P2860

Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study

http://www.wikidata.org/entity/Q28273981

description

2012 nî lūn-bûn

@nan

2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Prevalence of and risk factors ...... es: a prospective cohort study

@ast

Prevalence of and risk factors ...... es: a prospective cohort study

@en

Prevalence of and risk factors ...... es: a prospective cohort study

@nl

type

label

Prevalence of and risk factors ...... es: a prospective cohort study

@ast

Prevalence of and risk factors ...... es: a prospective cohort study

@en

Prevalence of and risk factors ...... es: a prospective cohort study

@nl

prefLabel

Prevalence of and risk factors ...... es: a prospective cohort study

@ast

Prevalence of and risk factors ...... es: a prospective cohort study

@en

Prevalence of and risk factors ...... es: a prospective cohort study

@nl

P1433

Q28273981-E7B19CED-7AB3-4330-8E5F-0814C811340C

P1476

Q28273981-68A5BFBA-94C8-4767-AAD6-064CAC09E326

P2093

Q28273981-00C8028C-50DA-4D6A-B7BC-D70EEEB10136

Q28273981-046595B2-1635-47E5-B43E-FA61A770E427

Q28273981-0AF38907-A27C-4671-873C-F080505EB199

Q28273981-0E99AFAD-9861-4505-B0F0-414C5614B012

Q28273981-116B0A9A-60F5-49B4-B1CF-F432568BDB22

Q28273981-11ECD4A3-4469-46BF-803A-CA5655C79F56

Q28273981-18073E0C-3FC1-4827-840F-6B6402EF80AD

Q28273981-192F9FEB-FA68-470E-8BB9-8F3DE261140D

Q28273981-1AED469B-5B00-4BFC-AA62-D4641AADA540

Q28273981-1B2287E2-9C7E-47E1-94E8-8E6DEAB5BDA8

P304

Q28273981-4E382124-1E77-4F19-B218-2063A4C4A8C5

P31

Q28273981-93042F9D-211B-4580-AE25-585D87CA2A71

P3181

Q28273981-525CB23D-593D-4C47-AC28-3831FD30FE5A

P356

Q28273981-62FE468D-045D-487E-839B-87A68064FEA4

P407

Q28273981-F130A629-00D4-4D4E-9F50-A17AF93D3D52

P433

Q28273981-B80134F2-023B-46FB-840B-624F6961396F

P478

Q28273981-A0A12F57-751A-427A-920D-4A63EF70EF47

P50

Q28273981-03E62DA2-D6EB-43F9-95CB-D90FC1073589

Q28273981-A54757A0-6CB6-4B44-A8FF-6C9CDD5DAE43

Q28273981-D5C79B46-3B08-4A9C-9E3C-F5713C40CD2E

Q28273981-EC55C629-4863-417C-B95F-A49C51CA7CD4

P577

Q28273981-BB01484D-6C20-4D76-8B65-64DB75536B0D

P698

Q28273981-FC517A6E-1ADE-4250-92E8-4B86D6FD6DA1

P921

Q28273981-1F3DE4EC-E640-4CE1-AE87-F46FB702B493

Q28273981-75B21B54-844A-4716-80E6-26A05AE2B63B

P3181

P356

S0140-6736(12)60734-X

P1433

P1476

Prevalence of and risk factors ...... es: a prospective cohort study

@en

P2093

Alena V Vorobyeva

http://www.w3.org/2001/XMLSchema#string

Allison Taylor

http://www.w3.org/2001/XMLSchema#string

Beverly Metchock

http://www.w3.org/2001/XMLSchema#string

Boris Y Kazennyy

http://www.w3.org/2001/XMLSchema#string

Carmen Contreras

http://www.w3.org/2001/XMLSchema#string

Carmen Suarez

http://www.w3.org/2001/XMLSchema#string

Chang-ki Kim

http://www.w3.org/2001/XMLSchema#string

Charlotte Kvasnovsky

http://www.w3.org/2001/XMLSchema#string

Eddy Valencia

http://www.w3.org/2001/XMLSchema#string

Ekaterina Kurbatova

http://www.w3.org/2001/XMLSchema#string

P304

1406-17

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

220116

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/S0140-6736(12)60734-X

http://www.w3.org/2001/XMLSchema#string

P407

P433

9851

http://www.w3.org/2001/XMLSchema#string

P478

380

http://www.w3.org/2001/XMLSchema#string

P50

Clifton E Barry

Isdore Chola Shamputa

P577

2012-10-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22938757

http://www.w3.org/2001/XMLSchema#string

P921

Akafuba bulwadde

multiple drug resistance